Compare Arko Corp. (ARKO) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Invesco Ltd. — how do they compare? Arko Corp. trades at $4.47 (market cap $493.06M), while Invesco Ltd. trades at $31.52 (market cap $13.85B). The key difference: Invesco Ltd. is far larger — about 28.1× Arko Corp.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| ARKO | IVZ | |
|---|---|---|
Market Cap | $493.06M | $13.85B |
Sector | Consumer Cyclical | Financials |
52-Week High | $8.64 | $32.01 |
52-Week Low | $3.82 | $20.67 |
Enterprise Value | $2.67B | $24.01B |
Dividend Yield | 2.73% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.51, down 4.04% amid a bearish technical trend. The stock shows mixed fundamentals: revenue declined to $7.64B in 2025, but net income improved to $22.74M. Recent Q2 2026 earnings missed estimates, with EPS of $0.04 versus $0.15 expected. The company maintains a dividend, paying $0.03 per share semi-annually, and holds a low P/S ratio of 0.06, though the P/E is elevated at 54.94. Analyst sentiment is neutral with all three covering analysts rating it Hold.
Outlook remains cautious due to declining revenue trends and competitive pressures in the convenience store sector. The stock's low price near recent support levels may attract value investors, but risks include volatile fuel margins and high debt. Institutional interest is present, with Dimensional Fund Advisors increasing its stake by 7.3% in Q2 2026.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
